BajettaE., ZilemboN., BuzzoniR., NoberascoC., CelioL., and BichisaoE.: Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy.Cancer Treat. Rev.,19: 31–36, 1993.
2.
BajettaE., ZilemboN., BuzzoniR., NoberascoC., Di LeoA., BartoliC., MersonM., SacchiniV., MogliaD., CelioL., and NelliP.: Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.Br. J. Cancer,70: 145–150, 1994.
3.
BajettaE., ZilemboN., BuzzoniR., NoberascoC., MartinettiA., FerrariL., BartoliC., SacchiniV., AttiliA., and LeperaP.: Formestane: effective therapy in postmenopausal women with advanced breast cancer.Ann. Oncol.,5: S15–S17, 1994.
4.
BajettaE., ZilemboN., Di LeoA., BuzzoniR., ZampinoM.G., BiganzoliL., and NoberascoC.: Hormone therapy in advanced breast carcinoma: present and future trends.Cancer Treat. Rev.,20: 241–258, 1994.
5.
BhatnagarA.S., HauslerA., SchieweckK., LangM., and BowmanR.: Highly selective inhibition of estrogen biosynthesis by CGS 20 267, a new non-steroidal aromatase inhibitor.J. Steroid Biochem. Mol. Biol.,37: 1021–1027, 1990.
6.
BisagniG., CocconiG., CeciG., FraschiniF., ScaglioneF., DickesI., and BichisaoE.: CGS 20 267 a new oral aromatase inhibitor: Phase I study in postmenopausal advanced breast cancer patients.J. Clin. Oncol. Proc. ASCO,12: 80 (Abstr. 122), 1993.
7.
CoombesR.C., GossP., DowsettM., GazetJ.C., and BrodieA.: 4-hydroxyandrostenedione treatment of postmenopausal patients with advanced breast cancer.Lancet,2: 1237–1239, 1984.
8.
CoombesR.C., HugesS.W.M., and DowsettM.: 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.Eur. J. Cancer,28: 1941–1945, 1992.
9.
di SalleE., OrnatiG., GiudiciD., LassusM., EvansT.R.J., and CoombesR.C.: Exemestane (FCE 24304), a new steroidal aromatase inhibitor.J. Steroid. Biochem. Molec. Biol.,43: 137–143, 1992.
10.
DowsettM., CunninghamD.C., SteinR.C., EvansS., DehenninL., HedleyA., and CoombesR.C.: Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.Cancer Res.,49: 1306–1312, 1989.
11.
DowsettM., GossP.E., PowlesT.J., HutchinsonG., BrodieA.H.M., JeffcosteS.L., and CoombesR.C.: Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer. Optimization of the therapeutic dose and route.Cancer Res.,47: 1957–1961, 1987.
12.
EvansT.R.J., di SalleE., OrnatiG., LassusM., Strolin BenedettiM., PianezzolaE., and CoombesR.C.: Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.Cancer Res.,52: 5933–5939, 1992.
13.
GiudiciD., OrnatiG., BriaticoG., BuzzettiF., LombardiP., and di SalleE.: 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor.J. Steroid Biochem.,30: 391–394, 1988.
14.
GossP.E., and GwynK.M.E.H.: Current perspectives on aromatase inhibitors in breast cancer.J. Clin. Oncol.,12: 2460–2470, 1994.
15.
GossP.E., PowlesT.J., and DowsettM.: Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report.Cancer Res.,46: 4823–4826, 1986;
16.
HarmesenH.J., and PorsiusA.J.: Endocrine therapy of breast cancer.Eur. J. Cancer Clin. Oncol.,24: 1099–1104, 1988.
17.
HöffkenL., JonatW., PossingerK., KolbelM., KunzT., WagnerH., BeckerR., CalliesR., FriederichP., WillmannsW., MaasH., and SchmidtC.G.: Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of post-menopausal patients with advanced breast cancer: a Phase II study.J. Clin. Oncol.,8: 875–880, 1990.
18.
IvesonT.J., SmithI.E., AhernJ., SmithersA.D., TrunetP.F., and DowsettM.: Phase I study of the oral nonsteroidal inhibitor CGS 20 267 in postmenopausal patients with advanced breast cancer.Cancer Res.,53: 266–270, 1993.
19.
JohnstonS.R.D., DowsettM., and SmithI.E.: Towards a molecular basis for tamoxifen resistance in breast cancer.Ann. Oncol.,3: 503–511, 1992.
20.
JonesA.L., Mac NeillF., JacobsS., LönningP.E., DowsettM., and PowlesT.J.: The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatase in breast cancer patients.Eur. J. Cancer,28: 1712–1716, 1992.
21.
LiptonA., DemersL.M., HarveyH.A., KambicK., GrossbergH., BrodyC., TrunetP.F., and SantenR.J.: CGS 20 267 - Phase I study of a new potent oral aromatase inhibitor in breast cancer.J. Clin. Oncol. Proc. ASCO,12: 58 (Abstr. 34), 1993.
22.
NoberascoC., BajettaE., ZilemboN., ZampinoM.G., MartinettiA., MagnaghiV., ZurloM.G.: A dose-finding study of a new steroidal aromatase inhibitor Exemestane, in postmenopausal patients with advanced breast cancer.J. Endocrinol. Invest.,17: 88 (Abstr. 85), 1994.
23.
PicklesT., PerryL., MurrayP., and PlowmanP.: 4-hydroxyandrostenedione - Further clinical and extended endocrine observations.Br. J. Cancer,62: 309–313, 1990.
24.
Plourde P.V., Yates R.A., Dyroff M., Dukes M., Dowsett M.A., Demers L.M., Webster A. and the Arimidex Study Group:The effect of Arimidex, a new potent aromatase inhibitor, on circulating estrogens in post-menopausal women.J. Clin. Oncol. Proc. ASCO,12: 91 (Abstr. 165), 1993.
25.
ReedM.J., LaiL.C., OwenA.M., SinghA., ColdhamN.G., PurohitA., GhilchkM.W., ShaikhN.A., and JamesV.H.T.: Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.Cancer Res.,50: 193–196, 1990.
26.
SteinR.C., DowsettM., and HadleyA.: Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione.Cancer Chemother. Pharmacol.,26: 75–78, 1990.
27.
TrunetP.F., MuellerP.H., BhatnagarA.S., DickesI., MonnetG., and WhiteG.: Open dose-finding study of a new potent and selective non-steroidal aromatase inhibitor, CGS 20 267, in healthy male subjects.J. Clin. Endocrinol. Metab.,17: 319–323, 1993.
28.
Van der WallE., DonkerT.H., de FrankrijkerE., NortierH.W.R., ThijssenJ.H.H., BlankensteinM.A.: Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women.Cancer Res.,53: 4563–4566, 1993.
29.
WoutersW., De CosterR., KrekelsM., Van DunJ., BeerensD., HaeltermanC., RalymaekersA., FreyneE., Van GelderJ., VenetM., JanssenP.A.Y.: R76713 a new specific non-steroidal aromatase inhibitor.J. Steroid Biochem.,32: 781–788, 1989.
30.
ZaccheoT., and di SalleE.: Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone.Cancer Chemother. Pharmacol.,25: 95–98, 1989.
31.
ZaccheoT., GiudiciD., LombardiP., and di SalleE.: A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors.Cancer Chemother. Pharmacol.,23: 47–50, 1989.
32.
ZilemboN., BuzzoniR., CelioL., NoberascoC., FerrariL., LaffranchiA., VicarioG., DolciS., and BajettaE.: Formestane as treatment of advanced breast cancer in elderly women.Tumori (in press).
